Abnormal production of the tumor necrosis factor inhibitor etanercept and clinical efficacy of tumor in a patient with PAPA syndrome
Authors:
- Fabrizio De BenedettiFBFabrizio De Benedetti
- Antonella InsalacoAIAntonella Insalaco
- Stefania CioschiSCStefania Cioschi
- Flaminia MuratoriFMFlaminia Muratori
- Leila E. D'UrbanoLDLeila E. D'Urbano
- Alberto G. UgazioAUAlberto G. Ugazio
- 1 December 2004
- journal article
- case report
- Published by Elsevier in The Journal of Pediatrics
- Vol. 145 (6) , 851-855
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Pyrin binds the PSTPIP1/CD2BP1 protein, defining familial Mediterranean fever and PAPA syndrome as disorders in the same pathwayProceedings of the National Academy of Sciences, 2003
- Targeted Disruption of Pyrin, the FMF Protein, Causes Heightened Sensitivity to Endotoxin and a Defect in Macrophage ApoptosisMolecular Cell, 2003
- The PAAD/PYRIN-Family Protein ASC Is a Dual Regulator of a Conserved Step in Nuclear Factor κB Activation PathwaysJournal of Experimental Medicine, 2002
- The InflammasomeMolecular Cell, 2002
- Mutations in CD2BP1 disrupt binding to PTP PEST and are responsible for PAPA syndrome, an autoinflammatory disorderHuman Molecular Genetics, 2002
- Enhanced cytokine mRNA levels in attack-free patients with familial Mediterranean feverGenes & Immunity, 2002
- Etanercept in Children with Polyarticular Juvenile Rheumatoid ArthritisNew England Journal of Medicine, 2000
- A New Autosomal Dominant Disorder of Pyogenic Sterile Arthritis, Pyoderma Gangrenosum, and Acne: PAPA SyndromeMayo Clinic Proceedings, 1997
- "Streaking Leukocyte Factor," Arthritis, and Pyoderma GangrenosumPediatrics, 1975